amed1q25ecsupplementalsl

1 Amedisys First Quarter 2025 Earnings Release Supplemental Slides April 23, 2025 EXHBIT 99.2

2 This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and uncertainties that could cause actual results to differ materially from those described in this presentation. You should not rely on forward-looking statements as a prediction of future events. Additional information regarding factors that could cause actual results to differ materially from those discussed in any forward-looking statements are described in reports and registration statements we file with the SEC, including our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, copies of which are available on the Amedisys internet website http://www.amedisys.com or by contacting the Amedisys Investor Relations department at (225) 292-2031. We disclaim any obligation to update any forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based except as required by law. www.amedisys.com NASDAQ: AMED We encourage everyone to visit the Investors Section of our website at www.amedisys.com, where we have posted additional important information such as press releases, profiles concerning our business, clinical operations and control processes and SEC filings. FORWARD-LOOKING STATEMENTS EXHBIT 99.2

3 HIGHLIGHTS AND SUMMARY FINANCIAL RESULTS (ADJUSTED): 1Q’25(1) 1. The financial results for the three-month periods ended March 31, 2024 and 2025 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period. 2. Same Store volume – Includes admissions and recertifications. 3. Same Store is defined as care centers that we have operated for at least the last 12 months and startups that are an expansion of a same store care center. 4. Free cash flow is defined as cash flow from operations less routine capital expenditures and required debt repayments. Growth Metrics: • Total Admissions: 999 (+31%) • Number of admitting JVs: 8 Other Statistics: • Patient Satisfaction: 90% High Acuity Care Adjusted Financial Results Same Store (3): • Admissions: +3.6% • ADC: -0.1% Other Statistics: • Revenue per Day: $179.48 (+3.7%) • Cost per day: $92.14 (+2.2%) HospiceHome Health Same Store(3) : • Admissions: +7% • Volume(2): +5% Other Statistics: • Medicare Revenue per Episode: $3,008 (+0.3%) • Cost per Visit: $119.99 (+2.9%) Amedisys Consolidated • Revenue: +4% • EBITDA: +15% • EBITDA Margin: 11.6% • Net Leverage ratio: 0.3x • Revolver availability: $508.0M • CFFO: $(3.7)M • DSO: 45.7 (vs. Q4’24 of 43.0 and down 8.4 days vs prior year) Amedisys Consolidated Amedisys Consolidated Regulatory 2025 Reimbursement • Final Hospice industry rule – industry estimated impact +2.9% increase (effective 10/1/24) • Final Home Health industry rule – industry estimated impact +0.5% increase (effective 1/1/25) 2026 Reimbursement • Proposed Hospice industry rule – industry estimated impact +2.4% increase (effective 10/1/25) $ in Millions, except EPS 1Q24 1Q25 Home Health 364.0$ 379.2$ Hospice 201.0 206.2 High Acuity Care 6.4 9.4 Total Revenue 571.4$ 594.8$ Gross Margin % 44.1% 44.2% Adjusted EBITDA 59.9$ 68.8$ 10.5% 11.6% Adjusted EPS 1.03$ 1.25$ Free cash flow(4) (16.6)$ (14.6)$ EXHBIT 99.2

4 55.7% 17.6% 26.7% Home Health Revenue Medicare FFS Private Episodic & Case Rate Per Visit 63.8% 34.6% 1.6% Amedisys Consolidated Revenue Home Health Hospice High Acuity Care • Medicare FFS: Reimbursed for a 30-day period of care • Private Episodic: MA and Commercial plans who reimburse us for a 30-day period of care or 60-day episode of care, majority of which range from 90% - 100% of Medicare rates • Case Rate: Managed care payors who reimburse us per admission • Per Visit: Managed care, Medicaid and private payors who reimburse us per visit performed 95.5% 4.5% Hospice Revenue Medicare FFS Private Hospice Per Day Reimbursement: • Routine Care: Patient at home with symptoms controlled, ~96% of the Hospice care provided • Continuous Care: Patient at home with uncontrolled symptoms • Inpatient Care: Patient in facility with uncontrolled symptoms • Respite Care: Patient at facility with symptoms controlled • Home Health: 347 care centers; 34 states & D.C. • Hospice: 164 care centers; 31 states • High Acuity Care: 8 admitting joint ventures; 7 states; 32 referring hospitals • Total: 519 care centers/joint ventures; 38 states and D.C. OUR REVENUE SOURCES: 1Q’25 EXHBIT 99.2

5 HOME HEALTH AND HOSPICE SEGMENT (ADJUSTED) – 1Q’25(1) • Medicare revenue per episode up 0.3% primarily due to the 0.5% rate increase effective 1/1/2025. • Y/Y Total CPV up $3.35 (+2.9%) primarily due to raises, wage inflation and an increase in salaried clinicians and clinical managers. • EBITDA margin decreased 20 basis points. Home Health Highlights • Net revenue per day +3.7% due to the +2.9% Hospice rate update effective 10/1/2024 and the mix in days. • Cost per day up $1.98 (+2.2%) primarily due to raises. • EBITDA margin up 60 basis points primarily due to the 2025 rate increase (effective 10/1/2024) partially offset by raises. Hospice Highlights 1. The financial results for the three-month periods ended March 31, 2024 and 2025 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period. 2. Pre-Corporate EBITDA does not include any corporate G&A expenses. 3. Same Store information represents the percent change in volume, admissions or ADC for the period as a percent of the volume, admissions or ADC of the prior period. 4. Same Store is defined as care centers that we have operated for at least the last 12 months and startups that are an expansion of a same store care center. $ in Millions 1Q24 1Q25 Medicare 215.8$ 211.2$ Non-Medicare 148.2 168.0 Home Health Revenue $364.0 $379.2 Gross Margin % 42.6% 42.3% Pre-Corporate EBITDA(2) $63.9 $66.1 17.6% 17.4% Operating Statistics Same Store Growth(3)(4) Admissions 10% 7% Volume 8% 5% Medicare revenue per episode $2,998 $3,008 Medicare recert rate 31.7% 31.4% Total cost per visit $116.64 $119.99 HOME HEALTH $ in Millions 1Q24 1Q25 Medicare 190.0$ 196.9$ Non-Medicare 11.0 9.3 Hospice Revenue $201.0 $206.2 Gross Margin % 47.9% 48.7% Pre-Corporate EBITDA(2) $48.8 $51.3 24.3% 24.9% Operating Statistics Admit growth - same store(3)(4) -3% 4% ADC growth - same store(3)(4) 0.3% -0.1% ADC 12,767 12,759 Avg. discharge length of stay 92 94 Revenue per day (net) $173.04 $179.48 Cost per day $90.16 $92.14 HOSPICE EXHBIT 99.2

6 GENERAL & ADMINISTRATIVE EXPENSES – ADJUSTED (1,2) Notes: • Year over year total G&A as a percentage of revenue decreased 80 basis points • $2.8 million increase in total G&A is primarily due to planned wage increases, employee-related insurance costs and higher information technology fees partially offset by lower legal fees and incentive compensation costs. • Total G&A decreased ~$7 million sequentially primarily due to a seasonality driven decrease in health insurance costs and lower incentive compensation costs. 1. The financial results for the three-month periods ended March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024 and March 31, 2025 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period. 2. Adjusted G&A expenses do not include depreciation and amortization. Impacted by raises and employee-related insurance costs. 33.8% 33.1% 33.7% 33.9% 33.0% 32.0% 34.0% 36.0% 1Q24 2Q24 3Q24 4Q24 1Q25 Total G&A as a Percent of Revenue G&A as a Percent of Revenue $ in Millions 1Q24 2Q24 3Q24 4Q24 1Q25 Home Health Segment - Total 91.0$ 92.4$ 93.3$ 95.5$ 94.6$ % of HH Revenue 25.0% 24.5% 25.0% 25.3% 24.9% Hospice Segment - Total 48.0 48.7 49.7 50.6 49.8 % of HSP Revenue 23.9% 23.9% 23.9% 23.8% 24.2% High Acuity Care Segment - Total 5.9 5.4 5.7 5.7 5.0 % of HAC Revenue 92.5% 55.1% 74.2% 70.4% 53.2% Total Corporate Expenses 48.4 49.2 49.6 50.8 46.7 % of Total Revenue 8.5% 8.3% 8.4% 8.5% 7.9% Total 193.3$ 195.7$ 198.3$ 202.7$ 196.1$ % of Total Revenue 33.8% 33.1% 33.7% 33.9% 33.0% 1Q24 2Q24 3Q24 4Q24 1Q25 Salary and Benefits 27.6$ 27.4$ 29.9$ 30.3$ 27.5$ Other 16.6 17.4 15.6 16.3 15.4 Corp. G&A Subtotal 44.2 44.8 45.5 46.6 42.9 Non-cash comp 4.2 4.4 4.1 4.2 3.8 Adjusted Corporate G&A 48.4$ 49.2$ 49.6$ 50.8$ 46.7$ EXHBIT 99.2

7 INDUSTRY LEADING QUALITY SCORES Quality of Patient Care (QPC) Patient Satisfaction (PS) • Amedisys maintains a 4-Star average in the Jan 2025 HHC Final release with 88% of our providers (representing 88% of care centers) at 4+ Stars and 46% of our providers (representing 42% of care centers) at 4.5+ Stars. •7 Amedisys providers (representing 11 care centers) rated at 5 Stars. Notes: (1) Jan 2025 QPC Star Final performance period = Apr 2023 – Mar 2024. (2) Jan 2025 PS Final performance period = Jul 2023 – Jun 2024. (3) QPC Star and PS Results for Amedisys Legacy providers only. (4) Only currently active care centers included in care center results. Metric Apr 24 Final Jul 24 Final Oct 24 Final Jan 25 Final Quality of Patient Care 4.35 4.32 4.24 4.18 Entities at 4+ Stars 95% 93% 89% 88% Metric Apr 24 Final July 24 Final Oct 24 Final Jan 25 Final Patient Satisfaction Star 3.72 3.77 3.78 4.02 Performance Over Industry +2% +3% +3% +4% 3.00 3.50 4.00 4.50 Apr 2022 Jul 2022 Oct 2022 Jan 2023 Apr 2023 Jul 2023 Oct 2023 Jan 2024 Apr 2024 Jul 2024 Oct 2024 Jan 2025 QPC Industry Performance Amedisys QPC Industry Avg QPC Top Competitor 3.00 3.50 4.00 4.50 Apr 2022 Jul 2022 Oct 2022 Jan 2023 Apr 2023 Jul 2023 Oct 2023 Jan 2024 Apr 2024 Jul 2024 Oct 2024 Jan 2025 PS Industry Performance Amedisys PS Industry Avg PS Top Competitor EXHBIT 99.2

8 HOSPICE QUALITY: AMEDISYS HOSPICE CONTINUES TO MOVE TOWARDS BEST-IN-CLASS Hospice Quality Notes: Included in the above analysis are only active providers. CMS Nat is an average of all providers nationally, excluding active AMED providers. EXHBIT 99.2

9 DEBT AND LIQUIDITY METRICS Net leverage ~0.3x 1. Net debt defined as total debt outstanding ($371.8M) less cash and cash equivalents ($284.9M). 2. Leverage ratio (net) is defined as net debt divided by last twelve months adjusted EBITDA ($254.7M). 3. Liquidity defined as the sum of cash balance and available revolving line of credit. Outstanding Term Loan 343.8$ Outstanding Revolver - Finance Leases 28.0 Total Debt Outstanding 371.8 Less: Deferred Debt Issuance Costs (1.3) Total Debt - Balance Sheet 370.5 Total Debt Outstanding 371.8 Less Cash & Cash Equivalents (284.9) Net Debt (1) 86.9$ Leverage Ratio (net) (2) 0.3 Term Loan 450.0$ Revolver Size 550.0 Borrowing Capacity 1,000.0 Revolver Size 550.0 Outstanding Revolver - Letters of Credit (42.0) Available Revolver 508.0 Plus Cash & Cash Equivalents 284.9 Total Liquidity (3) 792.9$ As of: 3/31/25 Credit Facility Outstanding Debt As of: 3/31/25 EXHBIT 99.2

10 CASH FLOW STATEMENT HIGHLIGHTS (1) 1Q’25 operating cash flow impacted by the timing of the payment of accounts payable and accrued expenses and a buildup in accounts receivable which is typical in the first quarter. 1. Free cash flow defined as cash flow from operations less routine capital expenditures and required debt repayments. $ in Millions 1Q24 2Q24 3Q24 4Q24 1Q25 GAAP net income (loss) 1 4.6$ 32.6$ 1 6.5$ (25.5)$ 61 .8$ Changes in working capital (36.8) 1 .0 7 5.2 34.0 (41 .7 ) Depreciation and amortization 6.1 6.4 6.8 6.7 6.8 Non-cash compensation 7 .9 8.3 6.2 8.2 6.8 Deferred income taxes 2.6 4.0 0.8 - 1 0.0 Impairment - - - 48.4 - Other (0.9) - 0.1 (1 .5) (47 .4) Cash flow from operations (6.5) 52.3 105.6 70.3 (3.7) Capital expenditures - routine (1 .2) (0.6) (1 .1 ) (0.9) (1 .2) Required debt repay ments (8.9) (9.4) (9.3) (9.6) (9.7 ) Free cash flow (16.6)$ 42.3$ 95.2$ 59.8$ (14.6)$ EXHBIT 99.2

11 INCOME STATEMENT ADJUSTMENTS (1) 1. The financial results for the three-month periods ended March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024 and March 31, 2025 have been adjusted for the certain items above. A reconciliation of our non-GAAP financial measures, which include these certain items, is included in the corresponding 8-K detailing quarterly results for each respective reporting period. 2. Other (income) expense, net includes a $48.1 million gain on an equity method investment recorded during the three-month period ended March 31, 2025. 1Q’25 adjustments primarily related to costs associated with pending merger and a gain on an equity method investment. $000s Income Statement Line Item 1Q24 2Q24 3Q24 4Q24 1Q25 G&A Merger-related expenses General and Administrativ e Expenses 20,667$ 1 1 ,901$ 1 6,669$ 1 7 ,401$ 1 6,7 69$ Impairment General and Administrativ e Expenses - - - 48,391 - Other Items Other (income) expense, net (2) Other Income (Expense) (37 1 ) (335) (538) (2,1 23) (48,67 2) Impairment Net Loss Attributable to Noncontrolling Interests - - - (5,867 ) - Total 20,296$ 11,566$ 16,131$ 57,802$ (31,903)$ EPS Impact 0.59$ 0.34$ 0.49$ 1.58$ (0.59)$ EBITDA Impact 20,296$ 11,566$ 16,131$ 57,802$ (31,903)$ EXHBIT 99.2